KIRhub 2.0
Sign inResearch Use Only

MAP3K6(MEKK6)

Sign in to save this workspace

UniProt O95382 · PDB · AlphaFold · Substrate: MBP · Clone: aa 620-950

Top inhibitors

#DrugInhibitionResidualKISSGini
1Ponatinib38.6%61.4%78.230.534
2Dabrafenib23.3%76.7%94.740.633
3Umbralisib19.2%80.8%98.740.670
4Tucatinib17.6%82.4%99.750.652
5Mitapivat16.2%83.8%100.000.625
6Selumetinib15.9%84.1%100.000.640
7Abrocitinib15.0%85.0%99.500.581
8Tepotinib14.4%85.6%99.750.727
9Avapritinib13.3%86.7%97.730.644
10Brigatinib13.0%87.0%82.960.513
11Zanubrutinib12.2%87.8%98.240.788
12Netarsudil11.3%88.7%93.220.676
13Fedratinib11.0%89.0%96.210.576
14Alpelisib10.7%89.3%97.220.720
15Bosutinib10.3%89.7%87.220.555
16Regorafenib10.1%89.9%95.990.719
17Everolimus9.9%90.1%100.000.706
18Pazopanib9.4%90.6%97.490.672
19Apatinib9.3%90.7%97.730.704
20Baricitinib9.2%90.8%97.990.616

Paralog block

No paralog group registered for this kinase.

EMT expression

  • Mesenchymal log2(TPM+1): 3.78
  • Epithelial log2(TPM+1): 3.14
  • Fold change: 0.65
  • Status: No significant change

Selectivity landscape vs inhibition on MAP3K6

Each point is one of the 92 approved drugs; color = inhibition % on MAP3K6.

3D structure

Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.

Annotations

Sign in to read and post annotations.

Loading…